share_log

T2 Biosystems | 8-K: Disclosure Information of Public Offering in Compliance With Nasdaq Listing Rule 5550(b)(2)

T2 Biosystems | 8-K: Disclosure Information of Public Offering in Compliance With Nasdaq Listing Rule 5550(b)(2)

T2 Biosystems | 8-K:爲符合納斯達克上市規則5550(b)(2)最低股東權益規定相關信息披露
美股sec公告 ·  05/23 04:56
牛牛AI助理已提取核心訊息
T2 Biosystems, a medical diagnostic company, has successfully regained compliance with the Nasdaq's market value of listed securities (MVLS) requirement for continued listing on the Nasdaq Capital Market. This development comes after the company was previously notified by Nasdaq on November 22, 2023, of its non-compliance due to its failure to maintain the minimum required MVLS of $35 million over a 30-day period. T2 Biosystems appealed for an exception and was granted until May 20, 2024, to demonstrate compliance. The company's successful compliance has been confirmed by Nasdaq on May 21, 2024. However, T2 Biosystems will be under a Mandatory Panel Monitor for one year, during which any failure to meet continued listing requirements could lead to delisting without additional time to regain compliance, although the company retains the right to request a new hearing before any delisting action is taken.
T2 Biosystems, a medical diagnostic company, has successfully regained compliance with the Nasdaq's market value of listed securities (MVLS) requirement for continued listing on the Nasdaq Capital Market. This development comes after the company was previously notified by Nasdaq on November 22, 2023, of its non-compliance due to its failure to maintain the minimum required MVLS of $35 million over a 30-day period. T2 Biosystems appealed for an exception and was granted until May 20, 2024, to demonstrate compliance. The company's successful compliance has been confirmed by Nasdaq on May 21, 2024. However, T2 Biosystems will be under a Mandatory Panel Monitor for one year, during which any failure to meet continued listing requirements could lead to delisting without additional time to regain compliance, although the company retains the right to request a new hearing before any delisting action is taken.
醫療診斷公司T2 Biosystems成功恢復了納斯達克上市證券市值(MVLS)要求繼續在納斯達克資本市場上市的要求。這一事態發展是在納斯達克此前於2023年11月22日通知該公司因未能在30天內維持3500萬美元的最低MVLS而違規行爲之後發生的。T2 Biosystems提出例外申請,並獲准在2024年5月20日之前獲得批准,以證明其合規性。該公司的成功合規性已於2024年5月21日得到納斯達克的確認。但是,T2 Biosystems將接受爲期一年的強制性小組監督,在此期間,任何未能滿足持續上市要求的行爲都可能導致在沒有更多時間恢復合規的情況下退市,儘管該公司保留在採取任何退市行動之前要求舉行新的聽證會的權利。
醫療診斷公司T2 Biosystems成功恢復了納斯達克上市證券市值(MVLS)要求繼續在納斯達克資本市場上市的要求。這一事態發展是在納斯達克此前於2023年11月22日通知該公司因未能在30天內維持3500萬美元的最低MVLS而違規行爲之後發生的。T2 Biosystems提出例外申請,並獲准在2024年5月20日之前獲得批准,以證明其合規性。該公司的成功合規性已於2024年5月21日得到納斯達克的確認。但是,T2 Biosystems將接受爲期一年的強制性小組監督,在此期間,任何未能滿足持續上市要求的行爲都可能導致在沒有更多時間恢復合規的情況下退市,儘管該公司保留在採取任何退市行動之前要求舉行新的聽證會的權利。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。